The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulationDexamethasone was used as an effective drug for severe COVID cases during the pandemic. A study integrating single-cell and bulk transcriptomics in clinical cohorts reveals the molecular basis of its immunomodulatory effect and also provides a framework for the future development of companion diagnostics for patient stratification in precision medicine.Dexamethasone was used as an effective drug for severe COVID cases during the pandemic. A study integrating single-cell and bulk transcriptomics in clinical cohorts reveals the molecular basis of its immunomodulatory effect and also provides a framework for the future development of companion diagnostics for patient stratification in precision medicine.Rainer Knoll, Elisa T. Helbig, Kilian Dahm, Olufemi Bolaji, Frederik Hamm, Oliver Dietrich, Martina van Uelft, Sophie Müller, Lorenzo Bonaguro, Jonas Schulte-Schrepping, Lev Petrov, Benjamin Krämer, Michael Kraut, Paula Stubbemann, Charlotte Thibeault, Sophia Brumhard, Heidi Theis, Gudrun Hack, Elena De Domenico, Jacob Nattermann, Matthias Becker, Marc D. Beyer, David Hillus, Philipp Georg, Constantin Loers, Janina Tiedemann, Pinkus Tober-Lau, Lena Lippert, Belén Millet Pascual-Leone, Frank Tacke, Gernot Rohde, Norbert Suttorp, Martin Witzenrath, CAPNETZ Study Group, Pa-COVID-19 Study Group, Antoine-Emmanuel Saliba, Thomas Ulas, Julia K. Polansky, Birgit Sawitzki, Leif E. Sander, Joachim L. Schultze, Anna C. Aschenbrenner, Florian Kurthhttps://www.cell.com/cell/fulltext/S0092-8674(24)00654-8?rss=yeshttp://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignJuly 4, 2024

Powered by WPeMatico